tiprankstipranks
Revvity, Inc. (MX:RVTY)
NYSE:RVTY
Mexico Market

Revvity (RVTY) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

RVTY Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
4 Buy
8 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Revvity
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVTY Stock 12 Month Forecast

Average Price Target

$1,927.65
▲(1.46% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $1,927.65 with a high forecast of $2,272.97 and a low forecast of $1,573.59. The average price target represents a 1.46% change from the last price of $1,900.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1572":"$1,572","2559":"$2,559","1818.75":"$1,818.8","2065.5":"$2,065.5","2312.25":"$2,312.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2272.9656963,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1927.6497539774998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.93K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1573.5916359,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.57K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1572,1818.75,2065.5,2312.25,2559],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1644.85,1693.1665920230769,1741.4831840461538,1789.7997760692308,1838.1163680923078,1886.4329601153847,1934.7495521384617,1983.0661441615384,2031.3827361846156,2079.6993282076924,2128.0159202307696,2176.3325122538463,2224.649104276923,{"y":2272.9656963,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1644.85,1666.6038272290384,1688.357654458077,1710.1114816871152,1731.8653089161537,1753.6191361451922,1775.3729633742307,1797.126790603269,1818.8806178323075,1840.634445061346,1862.3882722903845,1884.1420995194228,1905.8959267484613,{"y":1927.6497539774998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1644.85,1639.368587376923,1633.887174753846,1628.405762130769,1622.9243495076923,1617.4429368846154,1611.9615242615384,1606.4801116384615,1600.9986990153845,1595.5172863923076,1590.0358737692309,1584.554461146154,1579.073048523077,{"y":1573.5916359,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2558.808,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1661.021,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1661.021,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1661.021,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1746.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1746.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1746.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1746.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1644.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1644.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 106, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1644.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 105, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1644.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 68, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1644.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,273Average Price Target$1,928Lowest Price Target$1,574
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:RVTY
Bernstein
Bernstein
$2,010.7
Hold
5.83%
Upside
Reiterated
07/22/26
Bernstein Sticks to Their Hold Rating for Revvity (RVTY)
Leerink Partners Analyst forecast on MX:RVTY
Leerink Partners
Leerink Partners
Buy
Reiterated
07/17/26
Revvity (RVTY) Receives a Buy from Leerink Partners
TD Cowen
$2,098.12$2,272.97
Buy
19.63%
Upside
Reiterated
07/15/26
Revvity price target raised to $130 from $120 at TD CowenRevvity price target raised to $130 from $120 at TD Cowen
Evercore ISI Analyst forecast on MX:RVTY
Evercore ISI
Evercore ISI
$1,923.28$2,185.54
Buy
15.03%
Upside
Reiterated
07/06/26
Revvity price target raised to $125 from $110 at Evercore ISIRevvity price target raised to $125 from $110 at Evercore ISI
Barclays Analyst forecast on MX:RVTY
Barclays
Barclays
$1,835.86
Hold
-3.38%
Downside
Reiterated
06/24/26
Barclays Remains a Hold on Revvity (RVTY)
Wolfe Research Analyst forecast on MX:RVTY
Wolfe Research
Wolfe Research
Hold
Initiated
06/01/26
Revvity assumed with a Peer Perform at Wolfe ResearchRevvity assumed with a Peer Perform at Wolfe Research
Bank of America Securities Analyst forecast on MX:RVTY
Bank of America Securities
Bank of America Securities
Hold
Reiterated
05/14/26
Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM), Humacyte (NASDAQ: HUMA) and Revvity (NYSE: RVTY)
Guggenheim Analyst forecast on MX:RVTY
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
05/11/26
Revvity (RVTY) Receives a Hold from Guggenheim
Stifel Nicolaus Analyst forecast on MX:RVTY
Stifel Nicolaus
Stifel Nicolaus
$1,923.28$1,748.44
Hold
-7.98%
Downside
Assigned
05/06/26
Revvity price target lowered to $100 from $110 at StifelRevvity price target lowered to $100 from $110 at Stifel
J.P. Morgan Analyst forecast on MX:RVTY
J.P. Morgan
J.P. Morgan
$1,678.5$1,573.59
Hold
-17.18%
Downside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Option Care Health (NASDAQ: OPCH) and OnKure Therapeutics (NASDAQ: OKUR)
Goldman Sachs Analyst forecast on MX:RVTY
Goldman Sachs
Goldman Sachs
$1,661.01$1,748.44
Hold
-7.98%
Downside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)
Robert W. Baird
$2,255.48$2,045.67
Buy
7.67%
Upside
Reiterated
05/04/26
Revvity price target lowered to $125 from $129 at BairdRevvity price target lowered to $125 from $129 at Baird
Nephron
$1,573.59
Hold
-17.18%
Downside
Upgraded
03/26/26
Revvity upgraded to Hold from Sell at Nephron ResearchRevvity upgraded to Hold from Sell at Nephron Research
Wells Fargo
$1,870.83$1,923.28
Hold
1.23%
Upside
Reiterated
02/03/26
Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)
UBS Analyst forecast on MX:RVTY
Unknown Analyst
UBS
Not Ranked
UBS
$2,010.7$2,098.12
Buy
10.43%
Upside
Reiterated
02/03/26
Revvity (RVTY) Receives a Buy from UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:RVTY
Bernstein
Bernstein
$2,010.7
Hold
5.83%
Upside
Reiterated
07/22/26
Bernstein Sticks to Their Hold Rating for Revvity (RVTY)
Leerink Partners Analyst forecast on MX:RVTY
Leerink Partners
Leerink Partners
Buy
Reiterated
07/17/26
Revvity (RVTY) Receives a Buy from Leerink Partners
TD Cowen
$2,098.12$2,272.97
Buy
19.63%
Upside
Reiterated
07/15/26
Revvity price target raised to $130 from $120 at TD CowenRevvity price target raised to $130 from $120 at TD Cowen
Evercore ISI Analyst forecast on MX:RVTY
Evercore ISI
Evercore ISI
$1,923.28$2,185.54
Buy
15.03%
Upside
Reiterated
07/06/26
Revvity price target raised to $125 from $110 at Evercore ISIRevvity price target raised to $125 from $110 at Evercore ISI
Barclays Analyst forecast on MX:RVTY
Barclays
Barclays
$1,835.86
Hold
-3.38%
Downside
Reiterated
06/24/26
Barclays Remains a Hold on Revvity (RVTY)
Wolfe Research Analyst forecast on MX:RVTY
Wolfe Research
Wolfe Research
Hold
Initiated
06/01/26
Revvity assumed with a Peer Perform at Wolfe ResearchRevvity assumed with a Peer Perform at Wolfe Research
Bank of America Securities Analyst forecast on MX:RVTY
Bank of America Securities
Bank of America Securities
Hold
Reiterated
05/14/26
Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM), Humacyte (NASDAQ: HUMA) and Revvity (NYSE: RVTY)
Guggenheim Analyst forecast on MX:RVTY
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
Hold
Reiterated
05/11/26
Revvity (RVTY) Receives a Hold from Guggenheim
Stifel Nicolaus Analyst forecast on MX:RVTY
Stifel Nicolaus
Stifel Nicolaus
$1,923.28$1,748.44
Hold
-7.98%
Downside
Assigned
05/06/26
Revvity price target lowered to $100 from $110 at StifelRevvity price target lowered to $100 from $110 at Stifel
J.P. Morgan Analyst forecast on MX:RVTY
J.P. Morgan
J.P. Morgan
$1,678.5$1,573.59
Hold
-17.18%
Downside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Option Care Health (NASDAQ: OPCH) and OnKure Therapeutics (NASDAQ: OKUR)
Goldman Sachs Analyst forecast on MX:RVTY
Goldman Sachs
Goldman Sachs
$1,661.01$1,748.44
Hold
-7.98%
Downside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)
Robert W. Baird
$2,255.48$2,045.67
Buy
7.67%
Upside
Reiterated
05/04/26
Revvity price target lowered to $125 from $129 at BairdRevvity price target lowered to $125 from $129 at Baird
Nephron
$1,573.59
Hold
-17.18%
Downside
Upgraded
03/26/26
Revvity upgraded to Hold from Sell at Nephron ResearchRevvity upgraded to Hold from Sell at Nephron Research
Wells Fargo
$1,870.83$1,923.28
Hold
1.23%
Upside
Reiterated
02/03/26
Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)
UBS Analyst forecast on MX:RVTY
Unknown Analyst
UBS
Not Ranked
UBS
$2,010.7$2,098.12
Buy
10.43%
Upside
Reiterated
02/03/26
Revvity (RVTY) Receives a Buy from UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revvity

3 Months
Success Rate
24/37 ratings generated profit
65%
Average Return
+3.02%
reiterated a buy rating 3 months ago
Copying Catherine Ramsey Schulte's trades and holding each position for 3 Months would result in 64.86% of your transactions generating a profit, with an average return of +3.02% per trade.
1 Year
Success Rate
23/37 ratings generated profit
62%
Average Return
+8.17%
reiterated a buy rating 3 months ago
Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 62.16% of your transactions generating a profit, with an average return of +8.17% per trade.
2 Years
Success Rate
10/15 ratings generated profit
67%
Average Return
+5.19%
reiterated a buy rating 15 days ago
Copying Daniel Brennan's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +5.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVTY Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
9
6
3
5
12
Hold
67
106
105
68
50
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
76
112
108
73
62
In the current month, RVTY has received 12 Buy Ratings, 50 Hold Ratings, and 0 Sell Ratings. RVTY average Analyst price target in the past 3 months is 1,927.65.
Each month's total comprises the sum of three months' worth of ratings.

RVTY Financial Forecast

RVTY Earnings Forecast

Next quarter’s earnings estimate for RVTY is $21.09 with a range of $20.58 to $21.46. The previous quarter’s EPS was $18.14. RVTY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 52.94% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.
Next quarter’s earnings estimate for RVTY is $21.09 with a range of $20.58 to $21.46. The previous quarter’s EPS was $18.14. RVTY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 52.94% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Sales Forecast

Next quarter’s sales forecast for RVTY is $12.26B with a range of $12.14B to $12.31B. The previous quarter’s sales results were $12.40B. RVTY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 75.00% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.
Next quarter’s sales forecast for RVTY is $12.26B with a range of $12.14B to $12.31B. The previous quarter’s sales results were $12.40B. RVTY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 75.00% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Stock Forecast FAQ

What is MX:RVTY’s average 12-month price target, according to analysts?
Based on analyst ratings, Revvity, Inc.’s 12-month average price target is 1,927.65.
    What is MX:RVTY’s upside potential, based on the analysts’ average price target?
    Revvity, Inc. has 1.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Revvity, Inc. a Buy, Sell or Hold?
          Revvity, Inc. has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.
            What is Revvity, Inc.’s share price target?
            The average share price target for Revvity, Inc. is 1,927.65. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,272.97 ,and the lowest forecast is $1,573.59. The average share price target represents 1.46% Increase from the current price of $1,900.
              What do analysts say about Revvity, Inc.?
              Revvity, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Revvity, Inc.?
                To buy shares of MX:RVTY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.